XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$5.43
0.02 (0.46%)
▲
5d:
-3.3%
30d:
-11.36%
90d:
-26.39%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
XERS is down 5.7% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 23 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XERS trading at deep discount. Market pricing in -10.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: XERS trading at deep discount. Market pricing in -10.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.79
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.18
40.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $5.42, which is considered oversold relative to its 30-day fair value range of $5.42 to $6.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.6) compared to its historical average (20.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XERS is in a downtrend. Immediate support is located at $5.25, while resistance sits at $5.68.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+106.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XERS is in a downtrend. Immediate support is located at $5.25, while resistance sits at $5.68.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+106.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.42 -
$6.49
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.3% below Wall St target ($11.14)
Fair Price Analysis
30-Day Fair Range
$5.42 -
$6.49
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.25
Resistance Level
$5.69
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.57
Wall Street Target
$11.14
(+106.3%)
Revenue Growth (YoY)
42.8%
Profit Margin
0.2%
Valuation Discount vs History
-10.7% cheaper
PE vs Historical
14.6 vs 20.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.7%
(market-implied from PE analysis)
1-Year Target
$4.86
(-10%)
2-Year Target
$4.37
(-19%)
3-Year Target
$3.94
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→21)
$5.54
(+3%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 160.4%)
$28.01
(+419%)
Base:
(SPY PE: 14.6, Growth: 160.4%)
$18.23
(+238%)
Bear:
(PE: 12.4, Growth: 160.4%)
$15.49
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.6 to 20.5
Stabilization Target:
$7.60
(+40.7%)
PE Expansion Potential:
+40.7%
Share & Embed Analysis
Last updated: March 30, 2026 10:27 AM ET
Data refreshes hourly during market hours. Next update: 11:27 AM
Data refreshes hourly during market hours. Next update: 11:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-03-02
Beth Hecht
SELL
16667 shares
2026-02-02
Kevin Mcculloch
SELL
15000 shares
2026-01-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 65 BUY |